Verdiva Bio
Verdiva Bio raises $411M Series A
Quick Facts
Verdiva Bio: Series A Funding Round
Verdiva Bio has successfully raised $411M in Series A funding.
Company Overview
Biotechnology therapeutics company
Funding Details
The Series A round was led by Atlas Venture, with participation from Polaris Partners.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2024
- Employees: 50+
- Category: HealthTech
Investment
Verdiva Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Series A
- Polaris Partners: Verified investor in Series A
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
